Canna~Fangled Abstracts

Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes

By January 31, 2021February 2nd, 2021No Comments
Hopefully, THCV could provide an optional platform for the treatment of life-threatening diseases.
. 2020 Jan 31;2(1):6.

doi: 10.1186/s42238-020-0016-7.

Amos Abioye 1, Oladapo Ayodele 2, Aleksandra Marinkovic 2, Risha Patidar 2, Adeola Akinwekomi 2, Adekunle Sanyaolu 3
Affiliations 

Abstract

Δ9-Tetrahydrocannabivarin (THCV) is a cannabis-derived compound with unique properties that set it apart from the more common cannabinoids, such as Δ9-tetrahydrocannabinol (THC). The main advantage of THCV over THC is the lack of psychoactive effects. In rodent studies, THCV decreases appetite, increases satiety, and up-regulates energy metabolism, making it a clinically useful remedy for weight loss and management of obesity and type 2 diabetic patients. The distinctions between THCV and THC in terms of glycemic control, glucose metabolism, and energy regulation have been demonstrated in previous studies. Also, the effect of THCV on dyslipidemia and glycemic control in type 2 diabetics showed reduced fasting plasma glucose concentration when compared to a placebo group. In contrast, THC is indicated in individuals with cachexia. However, the uniquely diverse properties of THCV provide neuroprotection, appetite suppression, glycemic control, and reduced side effects, etc.; therefore, making it a potential priority candidate for the development of clinically useful therapies in the future. Hopefully, THCV could provide an optional platform for the treatment of life-threatening diseases.

 

Keywords: Cannabis sativa (marijuana), Diabetes, Obesity, Tetrahydrocannabinol (THC), Δ9-Tetrahydrocannabivarin (THCV)

References

    1. Anavi-Goffer S, Baillie G, Irving AJ, et al. Modulation of L-α-lysophosphatidylinositol / GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J Biol Chem. 2012;287:91–104. – DOI
    1. Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy. 2013;33(2):195–209. – DOI
    1. Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P T. 2017;42(3):180. – PubMed – PMC
    1. Brown AJ. Novel cannabinoid receptors. Br J Pharmacol. 2007;152(5):567–75. – DOI
    1. Buggy Y, Cornelius V, Wilton L, Shakir SA. Risk of depressive episodes with rimonabant: a before and after modified prescription event monitoring study conducted in England. Drug Saf. 2011;34:501–9. – DOI

Publication types

Leave a Reply